Back to mobile site

TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)

January 2, 2026 8:56 AM EST Send to a Friend
TD Cowen analyst Ritu Baral reiterated a Buy rating and $353.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login